Status:
NOT_YET_RECRUITING
Network Pharmacology Was Applied to Explore the Mechanism of Remimazolam Applied in General Anesthesia for Gynecological Surgeries
Lead Sponsor:
Second Hospital of Shanxi Medical University
Conditions:
Gynecological Disease
Eligibility:
FEMALE
18-64 years
Phase:
NA
Brief Summary
To explore the related mechanisms by which remimazolam regulates hemodynamic stability, inflammatory factors and the immune system in patients undergoing general anesthesia for gynecological surgeries...
Detailed Description
①Clinical effect evaluation of remimazolam 1. Compare the hemodynamic stability (heart rate, mean arterial pressure, blood oxygen saturation), anesthesia efficiency (induction time, recovery time), a...
Eligibility Criteria
Inclusion
- The patient or their family members sign the informed consent form
- Age: 18-64 years old, BMI: 18-30kg/m2
- ASA Grade Ⅰ or Ⅱ
- Patients undergoing gynecological surgeries (laparoscopic total hysterectomy, adnexectomy and myomectomy)
Exclusion
- People who are allergic to remimazolam or benzodiazepinesThyroid disease
- Long-term use of benzodiazepines
- Pregnancy or lactation
- Have a history of drug abuse or alcoholism
- Patients with contraindications for surgery
- Patients with hypertension (clinically diagnosed with hypertension) and patients with coronary heart disease (with typical angina pectoris symptoms and excluding aortic valve lesions, with a clear history of old myocardial infarction, with a clear history of acute myocardial infarction, and CAG finding coronary artery stenosis greater than or equal to 70%)
- Patients with arrhythmia, heart failure, renal failure, and those who have recently taken cardiovascular active drugs
- Endocrine disorders such as hyperthyroidism and pheochromocytoma that may affect the hemodynamic level of the body
- Patients with ketoacidosis and lactic acidosis
- Abnormal liver function, ALT\> three times the upper limit of the normal value;
- Renal failure (serum creatinine \>3mg/dl or creatinine clearance rate \<30ml/min)
- Patients who have been using sedatives or antidepressants for a long time, or have a history of alcohol abuse or drug dependence
- Asthma or reactive airway diseases
- Combined with underlying cognitive function abnormalities
- Exclusion criteria for research subjects
- Those who were mistakenly included without meeting the inclusion criteria
- Those who experienced adverse events such as shock, severe hypotension and severe arrhythmia during the operation
Key Trial Info
Start Date :
June 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2026
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06990763
Start Date
June 1 2025
End Date
January 1 2026
Last Update
May 25 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.